We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




bioMérieux Acquires Day Zero Diagnostics Solutions and Technologies

By LabMedica International staff writers
Posted on 17 Jun 2025

bioMérieux (Marcy l’Étoile, France), a world leader in the field of in vitro diagnostics, has agreed to acquire the assets of Day Zero Diagnostics (Watertown, MA, USA), an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. More...

 

This strategic acquisition aims to enhance bioMérieux's capabilities in next-generation sequencing (NGS) and rapid diagnostics, further solidifying its commitment to advancing healthcare and Antimicrobial Stewardship through innovative solutions. Day Zero Diagnostics has developed groundbreaking technologies that integrate direct-from-whole-blood sample preparation, sequencing, and advanced ID/AST analytics.

The sequencing-based rapid diagnostic in development by Day Zero Diagnostics can identify, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. Current approaches take 2-5 days to provide similar information. The assets to be acquired include NGS workflows, chemistries, reagents, as well as the bioinformatics pipeline and software. The integration of Day Zero Diagnostics solutions, which are still in the development phase, will reinforce bioMérieux’s R&D pipeline with fast and accurate testing tools to address unmet needs in infectious disease diagnostics, enabling the management of the most life-threatening conditions, including sepsis.

“Thanks to this strategic acquisition, we will broaden our capabilities in next-generation sequencing (NGS), following a proactive and forward-thinking approach to innovation. Sequencing is a promising technology that offers several advantages,” said Céline Roger-Dalbert, Executive Vice President, Research & Development, bioMérieux. ‘It enables diagnosis to be approached without necessarily having a hypothesis about the causes of infection, and results are obtained more rapidly, which is crucial for the diagnosis of infectious diseases.”

“The acquisition of Day Zero Diagnostics’ next-generation sequencing assets is a strategic fit with bioMérieux’s long-term vision,” added Pierre Boulud, Chief Executive Officer, bioMérieux. “Once fully developed, it will complement our existing infectious diseases diagnostic solutions already available on the market. By bringing sequencing technologies into routine fully automated testing, we will provide clinicians with an additional, powerful tool—especially valuable in cases of suspected bloodstream infections or other critical conditions where rapid, actionable results are essential for patient care. This investment reflects bioMérieux’s ongoing commitment to innovation and our mission to advance public health worldwide.”

Related Links:
bioMérieux
Day Zero Diagnostics


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.